Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Dna X (SONM) over the last 7 years, with Q3 2025 value amounting to 45.47%.

  • Dna X's Return on Capital Employed rose 463100.0% to 45.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 45.47%, marking a year-over-year increase of 463100.0%. This contributed to the annual value of 8.1% for FY2024, which is 81300.0% down from last year.
  • Latest data reveals that Dna X reported Return on Capital Employed of 45.47% as of Q3 2025, which was up 463100.0% from 85.86% recorded in Q2 2025.
  • In the past 5 years, Dna X's Return on Capital Employed registered a high of 45.47% during Q3 2025, and its lowest value of 85.86% during Q2 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 1.14% (2021), whereas its average is 6.05%.
  • Examining YoY changes over the last 5 years, Dna X's Return on Capital Employed showed a top increase of 463100bps in 2025 and a maximum decrease of -853000bps in 2025.
  • Dna X's Return on Capital Employed (Quarter) stood at 2.04% in 2021, then soared by 61bps to 0.8% in 2022, then surged by 103bps to 0.02% in 2023, then tumbled by -234965bps to 47.85% in 2024, then surged by 195bps to 45.47% in 2025.
  • Its Return on Capital Employed was 45.47% in Q3 2025, compared to 85.86% in Q2 2025 and 9.56% in Q1 2025.